Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
Da‐Liang Ou(National Taiwan University), Chiun Hsu(National Taiwan University Hospital)
Cited by 144
Related Papers
Alcoholism and Alcoholic Organ Damage and Genetic Polymorphisms of Alcohol Metabolizing Enzymes in Chinese Patients
|Hepatology|1997|124
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis
|The Lancet Oncology|2024|64
Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression
|Clinical Cancer Research|2015|49